ERN1 and familial pancreatic carcinoma: The studies were then expanded and dose-responses of three different IRE1α inhibitors (HNA, 3ETH, toyocamycin) were tested against a panel of 11 pancreatic cancer cell lines (Panc0203, Panc0327, Panc0403, SU8686, MiaPaCa2, Panc1, Panc0813, AsPC1, BxPc3, Panc0203, Panc1005) using an in vitro proliferation assay (MTT).